Clearmind Medicine Inc. (CMND)
1.36
-0.01 (-0.73%)
At close: Jan 30, 2025, 3:59 PM
1.35
-0.74%
After-hours Jan 30, 2025, 04:09 PM EST
Company Description
Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems.
It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors.
The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021.
Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.
Clearmind Medicine Inc.
| Country | CA |
| IPO Date | Nov 15, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Dr. Adi Zuloff-Shani Ph.D. |
Contact Details
Address: 1220 West 6th Avenue Vancouver, BC CA | |
| Website | https://www.clearmindmedicine.com |
Stock Details
| Ticker Symbol | CMND |
| Exchange | NASDAQ |
| Fiscal Year | November - October |
| Reporting Currency | USD |
| CIK Code | 0001892500 |
| CUSIP Number | n/a |
| ISIN Number | CA1850534027 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Adi Zuloff-Shani Ph.D. | Chief Executive Officer |
| Alan Mark Rootenberg B.Com., B.Comm, C.A., CPA | Chief Financial Officer |
| Adi Varon | Controller |
| Mylene Touboul | Accounting Manager |
| Prof. Mark Haden M.S.W. | Vice President of Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 22, 2025 | POS AM | Filing |
| Jan 22, 2025 | 20-F | Filing |
| Jan 07, 2025 | 6-K | Filing |
| Jan 06, 2025 | 6-K | Filing |
| Jan 02, 2025 | 6-K | Filing |
| Dec 09, 2024 | S-8 | Filing |
| Dec 06, 2024 | 6-K | Filing |
| Nov 20, 2024 | 6-K | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 10, 2024 | 6-K | Filing |